Table 1.
Association summary statistics of three significant CNV segments at 2q14.3 associated with DAS28-based response to TNF-α blocker therapy in 357 patients with RA
| Non-responders; n (%) | Responders; n (%) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Chr | Region | OR of being NR by deletion (95% CI) | CN = 1 | CN = 2 | CN = 3 | CN = 1 | CN = 2 | CN = 3 | P |
| 2 | 129,459,141–129,461,606 | 8.44 (2.77 to 25.71) | 7 (22.9%) | 25 (78.1%) | 0 (0.0%) | 13 (4.0%) | 311 (95.7%) | 1 (0.3%) | 1.67 × 10−4 |
| 2 | 129,457,798–129,458,197 | 7.88 (2.58 to 24.05) | 7 (22.9%) | 25 (78.1%) | 0 (0.0%) | 14 (3.8%) | 310 (95.4%) | 1 (0.3%) | 2.72 × 10−4 |
| 2 | 129,458,197–129,459,141 | 7.24 (2.41 to 21.76) | 7 (22.9%) | 25 (78.1%) | 0 (0.0%) | 15 (4.2%) | 309 (95.1%) | 1 (0.3%) | 4.07 × 10−4 |
The copy number of 0 or ≥ 4 were not observed in the study subjects
DAS28 disease activity scores based on 28 joint counts, Chr chromosome, OR odds ratio, NR non-responders, CI confidence interval, CN copy number